Doug Brunk is a San Diego-based award-winning reporter who began covering health care in 1991. Before joining the company, he wrote for the health sciences division of Columbia University and was an associate editor at Contemporary Long Term Care magazine when it won a Jesse H. Neal Award. His work has been syndicated by the Los Angeles Times and he is the author of two books related to the University of Kentucky Wildcats men's basketball program. Doug has a master’s degree in magazine journalism from the S.I. Newhouse School of Public Communications at Syracuse University. Follow him on Twitter @dougbrunk.
News
EMA validates marketing authorization application for delgocitinib cream
Delgocitinib is being evaluated for the treatment of chronic hand eczema in adults.
News
Low-dose oral minoxidil for female pattern hair loss: Benefits, impact on BP, heart rate evaluated
“It was surprising how little ambulatory blood pressure and heart rate changed after an average of 6 months of treatment,” one of the authors said...
News
Analysis reveals recent acne prescribing trends
The study period covered a mean of 1.9 million acne encounters per year.
News
Study aims to better elucidate CCCA in men
"We hope the data will prompt clinicians to assess for CCCA and risk factors in adult males with scarring alopecia," the researchers wrote.
News
Despite recent uptick in cases, leprosy is very rare, expert says
Over the past several years, 150-250 cases of leprosy have been reported each year.
News
Study validates use of new psoriatic arthritis prediction tool
To develop the tool, researchers evaluated 635 patients with psoriasis from a prospective longitudinal cohort study evaluating risk factors for...
News
Study highlights diagnostic challenges of differentiating lichen sclerosus from vitiligo
The investigators aimed to characterize differences in LS and vitiligo based on history, physical exam, and demographic findings at the initial...
News
Roflumilast cream appears safe, effective for children with psoriasis, researchers report
In children aged 2-11 years, roflumilast cream 0.3% was well tolerated and improved signs and symptoms of psoriasis, researchers report.
News
Study evaluating in utero treatment for hypohidrotic ectodermal dysplasia seeks enrollees
Researchers are seeking to enroll mothers 18 years of age and older who are genetically confirmed carriers of the XLEHD mutation and pregnant with...
News
What factors cause multiple biologic failure in psoriasis?
“Prior cross-sectional and single-center studies have primarily analyzed therapeutic failure of a single biologic or biologics within one class,”...
News
Study examines burden of vitiligo in the U.S.
The burden of vitiligo in the United States is poorly understood, according to the authors of the study.
News
FDA approves cantharidin for molluscum contagiosum
The development marks the first FDA-approved treatment for the condition.
News
Study examines pediatric skin biopsy trends at a tertiary care center
The five most common biopsy results were compound nevus, pyogenic granuloma, spongiotic dermatitis, intradermal nevus, and pilomatricoma.
News
EU agency issues positive opinion on ritlecitinib
In June, ritlecitinib was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.
News
What makes teens choose to use sunscreen?
Of the studies that examined the role of ethnicity on sunscreen use in a systematic review, White high school students were more likely to use...